Market Overview

CICC Raises Price Target on Mindray Medical Following Management Meeting

Related MR
Benzinga's M&A Chatter for Thursday September 10, 2015
Mindray Announces Receipt of Revised Non-binding Proposal to Acquire the Company at $27 per ADS or $27 per Ordinary Share

China International Capital raised its price target on Mindray Medical (NYSE: MR) from $37.00 to $44.00 and maintained a Buy rating on the stock.

In the report, China International Capital stated, "Management shed more light on the 2013 outlook, where China and Emerging markets will remain the key growth drivers, while developed markets hold strategic value despite their minor contribution to near term profitability."

Mindray Medical closed Wednesday at $37.69.

Latest Ratings for MR

Jun 2015JMP SecuritiesUpgradesUnderperformMarket Perform
Mar 2015Credit SuisseDowngradesNeutralUnderperform
Mar 2015JMP SecuritiesMaintainsMarket Underperform

View More Analyst Ratings for MR
View the Latest Analyst Ratings

Posted-In: China International Capital Corp.Analyst Color Price Target Analyst Ratings


Related Articles (MR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters